New research indicates that people who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain lost weight far faster than those who halt conventional diet and exercise regimens.
Findings released in a major health publication demonstrates that while overweight people often shed a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Users buying these drugs should be cognizant of the danger of fast weight regain when the medication ends," cautioned researcher Dr. Susan Jebb.
This pace of regain means a return to original mass in about one and a half years.
Comparing Treatments
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of these new drugs with older methods.
The team point out that individuals who lose weight through dieting generally see a more gradual creep back—around 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Doctors believe the way of the drugs accounts for the accelerated rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in appetite is unsuppressed, making binge eating much more probable."
A Chronic Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the therapy is often long-term.
This view is echoed by drug manufacturers, who state that the findings "underscore the long-term character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Users who have stopped the medication explain a sudden resurgence of cravings.
"It felt as if something that goes on and you become starving," described one woman.
This challenge is exacerbated if users have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is greater among females than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined behavioural management.
